{"nctId":"NCT04308668","briefTitle":"Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","startDateStruct":{"date":"2020-03-17","type":"ACTUAL"},"conditions":["Corona Virus Infection","Acute Respiratory Distress Syndrome","SARS-CoV Infection","Coronavirus","Coronavirus Infections"],"count":1312,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Hydroxychloroquine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Hydroxychloroquine","otherNames":["Plaquenil"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent\n* Exposure to a COVID19 case within 4 days as either a household contact or occupational exposure, OR\n* Symptomatic COVID19 case with confirmed diagnosis within 4 days of symptom onset OR symptomatic high risk exposure with known COVID19 contact and within 4 days of symptom onset;\n\nExclusion Criteria:\n\n* Current hospitalization\n* Allergy to hydroxychloroquine\n* Retinal eye disease\n* Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency\n* Known chronic kidney disease, stage 4 or 5 or receiving dialysis\n* Structural or ischemic heart disease\n* Personal or Family History of Prolonged QT syndrome\n* Weight \\< 50 kg\n* Known Porphyria\n* Current use of: hydroxychloroquine or cardiac medicines of: flecainide, Tambocor; amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or Procan, Procanbid, propafenone, Rythmal, sotalol;\n* Current use of medicines which prolong the QT interval including:\n\n  * Antimicrobials: levofloxacin, ciprofloxacin, moxifloxacin, azithromycin, clarithromycin, erythromycin, ketoconazole, itraconazole, or mefloquine\n  * Antidepressants: amitriptyline, citalopram, desipramine, escitalopram, imipramine, doxepin, fluoxetine, wellbutrin, or venlafaxine\n  * Antipsychotic or mood stabilizers: haloperidol, droperidol, lithium, quetiapine, thioridazine, ziprasidone\n  * Methadone\n  * Sumatriptan, zolmitriptan","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline","description":"Number of participants at 14 days post enrollment with active COVID19 disease among those who were asymptomatic at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline","description":"Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":".12"},{"groupId":"OG001","value":"-2.33","spread":".12"}]}]}]},{"type":"SECONDARY","title":"Rate of Hospitalization","description":"Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Death","description":"Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Confirmed SARS-CoV-2 Detection","description":"Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)","description":"Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID-19 infection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of All-Cause Study Medicine Discontinuation or Withdrawal","description":"Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Symptom Severity at 5 and 14 Days","description":"Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":null},{"groupId":"OG001","value":"-2.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.36","spread":null},{"groupId":"OG001","value":"-3.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry","description":"Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the number of participants who report a score of 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":658},"commonTop":["Nausea or upset stomach","Diarrhea, abdominal pain, vomiting","Irritability, dizziness, vertigo","Tinnitus","Headache"]}}}